Abstract: Described herein are pyridinone-based compounds, derivatives thereof, and pharmaceutical formulations thereof. In some aspects, the pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can be administered to a subject in need thereof. In some aspects, pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can modulate an activity and/or a function of a BRD protein and/or BET protein.

Abstract: In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of treating one or more clinical conditions associated with estrogen receptor, such as a cancer, including breast cancer, or osteoporosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of treating one or more clinical conditions associated with estrogen receptor, such as a cancer, including breast cancer, or osteoporosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Described herein are pyridinone-based compounds, derivatives thereof, and pharmaceutical formulations thereof. In some aspects, the pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can be administered to a subject in need thereof. In some aspects, pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can modulate an activity and/or a function of a BRD protein and/or BET protein.

Abstract: Described herein are pyridinone-based compounds, derivatives thereof, and pharmaceutical formulations thereof. In some aspects, the pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can be administered to a subject in need thereof. In some aspects, pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can modulate an activity and/or a function of a BRD protein and/or BET protein.

Abstract: Described herein are pyridinone-based compounds, derivatives thereof, and pharmaceutical formulations thereof. In some aspects, the pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can be administered to a subject in need thereof. In some aspects, pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can modulate an activity and/or a function of a BRD protein and/or BET protein.

Abstract: A high voltage integrated circuit device includes a semiconductor substrate having a surface region with a contact region, which is coupled to a source/drain region. The device has a plasma enhanced oxide overlying the surface region, a stop layer overlying the plasma enhanced oxide, and a contact opening through a portion of the stop layer and through a portion of the plasma enhanced oxide layer. The contact opening exposes a portion of the contact region without damaging it. The device has a silicide layer overlying the contact region to form a silicided contact region and an interlayer dielectric overlying the silicided contact region to fill the contact opening and provide a thickness of material overlying the stop layer. An opening in the interlayer dielectric layer is formed through a portion of the thickness to expose a portion of the silicided contact region and expose a portion of the stop layer.

Abstract: A high voltage integrated circuit device includes a semiconductor substrate having a surface region with a contact region, which is coupled to a source/drain region. The device has a plasma enhanced oxide overlying the surface region, a stop layer overlying the plasma enhanced oxide, and a contact opening through a portion of the stop layer and through a portion of the plasma enhanced oxide layer. The contact opening exposes a portion of the contact region without damaging it. The device has a silicide layer overlying the contact region to form a silicided contact region and an interlayer dielectric overlying the silicided contact region to fill the contact opening and provide a thickness of material overlying the stop layer. An opening in the interlayer dielectric layer is formed through a portion of the thickness to expose a portion of the silicided contact region and expose a portion of the stop layer.